News - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

76 to 100 of 401 results

Vertex sells Incivo royalty rights to Janssen for $152 million

21-11-2013

Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Gilead's Vitekta gains European Commission approval

Gilead's Vitekta gains European Commission approval

18-11-2013

The European Commission has granted marketing authorization for US biotech firm Gilead Sciences’ Vitekta…

Anti-viralsBiotechnologyelvitegravirEuropeGilead SciencesRegulationVitekta

Influenza products market to grow at a CAGR of 8% through 2018

14-11-2013

The influenza products market, including vaccines, antivirals and diagnostic products, has been forecast…

Anti-viralsGlobalMarkets & MarketingPharmaceutical

Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy

08-11-2013

US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

ViiV Healthcare’s Tivicay approved in Canada for HIV

04-11-2013

ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

03-11-2013

US drug major Bristol-Myers Squibb has filed a New Drug Application with Japan’s Pharmaceutical and…

Anti-viralsAsia-PacificasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalRegulation

AHF sues Johnson & Johnson over AIDS drug pricing

AHF sues Johnson & Johnson over AIDS drug pricing

01-11-2013

The Washington DC, USA-based AIDS Healthcare Foundation (AHF) has filed a law suit in the Superior Court…

Anti-viralsJanssenJohnson & JohnsonLegalNorth AmericaPharmaceuticalPricing

New HIV drugs drive Gilead Sciences 3rd-qtr growth

New HIV drugs drive Gilead Sciences 3rd-qtr growth

30-10-2013

US biotech Gilead Sciences late yesterday reported strong third-quarter 2013 financial results that were…

Anti-viralsBiotechnologyFinancialGilead Sciences

First ever flu vaccine developed by Chinese researchers

28-10-2013

Chinese researchers have successfully developed the vaccine for the H7N9 bird flu virus, after the flu…

Anti-viralsAsia-PacificPharmaceuticalResearchTianyuan Bio-Pharmaceutical

Unanimous yes vote from FDA advisory panel for Gilead’s sofosbuvir in hep C

Unanimous yes vote from FDA advisory panel for Gilead’s sofosbuvir in hep C

27-10-2013

Following swiftly on a similar decision for Janssen’s hepatitis C drug simeprevir, the US Food and…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaRegulationsofosbuvir

EMA advises on compassionate use of sofosbuvir for hepatitis C

EMA advises on compassionate use of sofosbuvir for hepatitis C

25-10-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given an…

Anti-viralsEuropeGilead SciencesPharmaceuticalRegulationsofosbuvir

DC AIDS protesters join push to demand China gives $1 billion to fight global AIDS

25-10-2013

The Washington DC, USA based AIDS Healthcare Foundation (AHF) is spearheading a series of US and global…

Anti-viralsAsia-PacificFinancialPharmaceuticalPolitics

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

25-10-2013

Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

FDA grants Merck’s hepatitis C treatment breakthrough designation

FDA grants Merck’s hepatitis C treatment breakthrough designation

23-10-2013

US pharma giant Merck & Co has announced that the US Food and Drug Administration has granted MK-5172/MK-8742…

Anti-viralsMerck & CoNorth AmericaPharmaceuticalRegulation

Deal worth $156m to provide HIV drugs for Africa

17-10-2013

The Global Fund to Fight AIDS, tuberculosis and malaria has signed a $156 million grant agreement with…

Anti-viralsHealthcarePharmaceuticalRest of the World

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

Gilead's HIV combo drug Stribild shows viral suppression after three years

Gilead's HIV combo drug Stribild shows viral suppression after three years

16-10-2013

Gilead Sciences has announced results from two Phase III studies for its combination drug Stribild in…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaResearchStribild

Vivaldi Biosciences acquires clinical stage influenza vaccine assets

13-10-2013

Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Valneva licenses EB66 to IAVI for preventive HIV vaccine

02-10-2013

Biotech firm Valneva says that it has licensed the use of its EB66 cell line to the International AIDS…

Anti-viralsBiotechnologyLicensingVaccinesValneva

Gilead’s HIV drug booster Tybost gets EU marketing authorization

Gilead’s HIV drug booster Tybost gets EU marketing authorization

27-09-2013

US biotech major Gilead Sciences has received marketing authorization from the European Commission for…

Anti-viralsBiotechnologyEuropeGilead SciencesNorth AmericaRegulationTybost

MSF warns of US/Indian tension over generic policy discussion

MSF warns of US/Indian tension over generic policy discussion

25-09-2013

Humanitarian group Médecins Sans Frontières has warned that India is facing political pressure from…

Anti-viralsAsia-PacificBayerGenericsGleevecHealthcareNexavarNorth AmericaNovartisPolitics

76 to 100 of 401 results

Back to top